I know nothing about charts, but the Alport drug, now called SAR339375 by Sanofi, is still progressing in a clinical trial. In March they opened a new study site in the UK, and in April, they added the INN name for the drug: lademirsen.
In my experience, companies only go to the bother of getting an INN if they are planning taking the drug forward into pivotal trials.
Relevance for RGLS is that they are due $10M when an interim recruitment milestone is reached in this trial, and potentially another $30M at the end of phase 2 – I guess some of this is dependent on taking the drug forward at this point.
Covid must have slowed (the already very slow!) recruitment, so maybe the share price increase is due to the INN being seen as increasing the chances of RGLS getting that $30M further down the line.